fda warning letters compounded semaglutide september 2025 issued 30 to telehealth companies for false and misleading claims about GLP-1 products. This marks the second round of enforcement action since the agency's crackdown on misleading GLP-1 Compounding: When Innovation May

Despite this, there are growing concerns over its serious side effects, including blood clots, DVTs, and pulmonary embolisms

Others leave out important context

In addition, with pancreatic perfusion, a GLP-1R agonist facilitated glucagon secretion from alpha cells via GLP-1R, also supporting the idea that active GLP-1R is present in alpha cells under diabetic conditions and such phenomena are likely involved in the paradoxical hyperglucagonaemia in type 2 diabetes

Brands launching GLP-1 Friendly foods across retail and foodservice As GLP-1 medications reshape eating habits, several food companies are launching products specifically designed to support smaller portions, higher satiety, and better nutritional balance

Retatrutide vs Tirzepatide Head-to-head comparison of the triple vs dual agonist

Sci China Life Sci